Novartis vet is getting another shot at mTOR following the implosion of a longevity pioneer
One of the upstarts in the longevity field has roped in some fresh discovery assets out of Novartis — along with a Novartis vet to head up their new subsidiary.
New York-based Cambrian Biopharma has licensed rights to mTOR programs from the Novartis Institutes for BioMedical Research — a Jay Bradner-led group that has been known to spin out assets from time to time when discovery projects don’t necessarily fit right into their core R&D focus.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.